Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Executive Summary

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22

You may also be interested in...



Will Three Be The Charm For FDA Review Of Antipsychotics For Pediatric Use?

FDA’s Psychopharmacologic Drugs Advisory Committee will evaluate pediatric indications for AstraZeneca’s Seroquel, Pfizer’s Geodon and Lilly’s Zyprexa during its June 9-10 meeting.

Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA

Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel